Kangstem Biotech Co., Ltd. (KOSDAQ:217730)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,471.00
+1.00 (0.07%)
Last updated: Oct 2, 2025, 9:00 AM KST
0.07%
Market Cap144.47B
Revenue (ttm)12.77B
Net Income (ttm)-8.28B
Shares Out94.05M
EPS (ttm)-152.96
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume322,566
Average Volume585,937
Open1,470.00
Previous Close1,470.00
Day's Range1,430.00 - 1,479.00
52-Week Range1,080.00 - 2,935.00
Beta0.73
RSI60.76
Earnings Daten/a

About Kangstem Biotech

Kangstem Biotech Co., Ltd. a biopharmaceutical company, develops stem cell therapeutic products for rare and incurable diseases. The company's stem cell therapy products include Furestem-AD for treatment of subacute and chronic atopic dermatitis; Furestem-RA to treat rheumatoid arthritis; and Furestem-CD for treatment of active crohn’s disease. It also provides stem cell conditioned media, such as umbilical cord blood-derived stem cell conditioned media that includes epidermal, vascular endothelium, keratinocyte, hepatocyte, transforming, and p... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2010
Employees 97
Stock Exchange KOSDAQ
Ticker Symbol 217730
Full Company Profile

Financial Performance

In 2023, Kangstem Biotech's revenue was 12.70 billion, a decrease of -22.06% compared to the previous year's 16.30 billion. Losses were -21.95 billion, 8.47% more than in 2022.

Financial Statements

News

There is no news available yet.